Evidence map›Paper›PMID 42081163›Full record

ArticleEndocrine2026

Long-term cardiovascular mortality risk of hyperuricemia and chronic kidney disease in a general Japanese population: NIPPON DATA90.

Koki Ono, Aya Hirata, Aya Kadota, Akiko Harada, Yasuyuki Nakamura, Takehito Hayakawa, Naoyuki Takashima, Akira Fujiyoshi, Yoshikuni Kita, Takayoshi Ohkubo and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Koki OnoDepartment of Preventive Medicine and Public Health, Keio University, Tokyo, Japan.
Aya HirataDepartment of Preventive Medicine and Public Health, Keio University, Tokyo, Japan. aya.hirata@keio.jp.
Aya KadotaNCD Epidemiology Research Center, Shiga University of Medical Science, Otsu, Japan.
Akiko HaradaNCD Epidemiology Research Center, Shiga University of Medical Science, Otsu, Japan.
Yasuyuki NakamuraNCD Epidemiology Research Center, Shiga University of Medical Science, Otsu, Japan.
Takehito HayakawaKinugasa Research Organization, Ritsumeikan University, Kyoto, Japan.
Naoyuki TakashimaNCD Epidemiology Research Center, Shiga University of Medical Science, Otsu, Japan.
Akira FujiyoshiDepartment of Hygiene, Wakayama Medical University, Wakayama, Japan.
Yoshikuni KitaNCD Epidemiology Research Center, Shiga University of Medical Science, Otsu, Japan.
Takayoshi OhkuboDepartment of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan.
Akira OkayamaResearch Institute of Strategy for Prevention, Tokyo, Japan.
Katsuyuki MiuraNCD Epidemiology Research Center, Shiga University of Medical Science, Otsu, Japan.
Tomonori OkamuraDepartment of Preventive Medicine and Public Health, Keio University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWhether hyperuricemia (HU) independently predicts cardiovascular disease (CVD) remains debated, whereas chronic kidney disease (CKD) is a well-established risk factor. This study assessed the independent and mediated association of HU in CKD on long-term CVD mortality in a 30-year nationwide Japanese cohort.

methodsData from NIPPON DATA90 participants aged ≥ 30 years enrolled in 1990 and followed for up to 30 years were used. HU was defined as serum uric acid ≥ 416.4 µmol/L, and CKD as an estimated glomerular filtration rate < 60 mL/min/1.73 m² or positive proteinuria. Four baseline categories were created (neither, HU-only, CKD-only, both conditions), and analyzed via Cox models to estimate hazard ratios (HR) for CVD mortality, adjusted for age, sex, hypertension, diabetes mellitus, dyslipidemia, BMI, and history of smoking/alcohol.

resultsAmong 7,336 participants (58.5% women; mean age 52.5 years), 807 CVD deaths occurred over a mean 24.2 years. At baseline, 86.6% had neither condition, 4.9% HU-only, 7.1% CKD-only, and 1.5% both. HU-only was not significantly associated with CVD mortality (HR 1.14, 0.81–1.61), CKD-only had significant association (1.28, 1.04–1.59), and both HU/CKD conditions had the highest risk (2.18, 1.50–3.18). Further analyses showed that HU-only was significant in women (2.44, 1.13–5.28) but not men (1.04, 0.71–1.52).

conclusionOverall, CKD and coexistent HU/CKD showed to be a significant CVD mortality risk, and HU’s association with CVD mortality may be partly mediated through CKD. This study observed that HU and CKD coexistence heighten the risk of CVD mortality. Integrated management of serum urate and renal health may aid long-term CVD prevention.

Indexed as

Cardiovascular DiseasesHyperuricemiaRenal Insufficiency, ChronicAdultAgedCohort StudiesEast Asian PeopleFemaleHumansJapanMaleMiddle AgedRisk FactorsUric AcidUric AcidCardiovascular diseaseChronic kidney diseaseCohort studyHyperuricemia

Identifiers

PMID42081163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.